Research shows that higher vitamin D levels predict better responses to biologic psoriasis medications. In a 2026 pilot study of 120 patients, those with excellent treatment responses had vitamin D levels nearly double those of poor responders (60.3 versus 30.3 nmol/L). According to Gram Research analysis, vitamin D independently predicted at least 90% improvement in psoriasis severity, suggesting doctors might use simple blood tests to predict which patients will benefit most from expensive biologic drugs before starting treatment.
A new pilot study from Northern Ireland examined whether simple blood tests could predict how well biologic medications work for psoriasis patients. Researchers tested 120 adults receiving biologic therapy and measured their vitamin D levels, body weight, and inflammation markers. According to Gram Research analysis, patients with higher vitamin D levels and lower inflammation showed much better treatment responses. The findings suggest doctors might use these three measurements to predict which patients will benefit most from expensive biologic drugs, helping create more personalized treatment plans for this common skin condition affecting millions worldwide.
Key Statistics
A 2026 cross-sectional pilot study of 120 psoriasis patients found that those with excellent biologic treatment responses had vitamin D levels of 60.3 nmol/L compared to 30.3 nmol/L in poor responders, a statistically significant difference (p < 0.001).
In the 2026 Northern Ireland pilot study, higher vitamin D levels independently predicted at least 90% improvement in psoriasis severity, with each additional nmol/L of vitamin D increasing the odds of excellent response by 3.2% (OR = 1.032, p < 0.001).
The 2026 study of 120 psoriasis patients found that higher body weight reduced the odds of being a Super-Responder to biologic therapy by 10.9% per unit increase in BMI (OR = 0.891, p = 0.027).
Among 120 psoriasis patients receiving biologic therapy in a 2026 pilot study, higher inflammation markers (C-reactive protein) reduced treatment stability, with each unit increase reducing the odds of maintaining stable therapy by 13.6% (OR = 0.864, p = 0.012).
The Quick Take
- What they studied: Whether vitamin D levels, body weight, and inflammation in the blood can predict how well biologic psoriasis medications will work for individual patients.
- Who participated: 120 adults in Northern Ireland who were already taking biologic medications for moderate to severe psoriasis. Researchers measured how well each person’s treatment was working.
- Key finding: Patients with higher vitamin D levels had much better treatment success. Those with the best results had vitamin D levels nearly twice as high as those who didn’t respond well (60.3 versus 30.3 nmol/L). Higher body weight and more inflammation in the blood predicted worse outcomes.
- What it means for you: If you have psoriasis and are considering biologic treatment, your doctor might soon be able to do simple blood tests to predict your chances of success. This could help avoid expensive treatments that won’t work for you. However, this is early research, and more studies are needed before doctors routinely use these tests.
The Research Details
This was a cross-sectional study, which means researchers looked at a group of people at one point in time rather than following them over months or years. The team enrolled 120 adults at Belfast City Hospital who were already receiving biologic therapy for psoriasis. They measured three things: vitamin D levels in the blood, body mass index (BMI, a measure of body weight relative to height), and C-reactive protein (CRP, a marker of inflammation in the body). Researchers then compared these measurements across different groups based on how well each person’s psoriasis responded to treatment. They used a standard scoring system called PASI (Psoriasis Area and Severity Index) to measure treatment response, categorizing patients as Super-Responders, Excellent Responders, and Frequent Switchers based on their improvement levels.
This research approach is important because it identifies potential predictive markers that could be measured before or early in treatment. Biologic medications are expensive and don’t work equally well for everyone. If doctors could predict who will respond best, they could make smarter treatment decisions, save money, and help patients avoid ineffective treatments. The cross-sectional design provides a quick snapshot of associations, though it cannot prove cause and effect.
This is a pilot study, meaning it’s preliminary research with a relatively small sample size (120 people). The findings are promising but need confirmation in larger studies before changing clinical practice. The study was conducted at a single hospital in Northern Ireland, so results may not apply equally to all populations. The researchers used established medical measurements and statistical methods, which strengthens the findings. However, the study design cannot prove that vitamin D causes better treatment response, only that the two are associated.
What the Results Show
The study found significant differences in vitamin D levels, body weight, and inflammation markers among different treatment response groups. Patients who had excellent responses to biologic therapy (defined as at least 90% improvement in their psoriasis) had substantially higher vitamin D levels compared to poor responders: 60.3 nmol/L versus 30.3 nmol/L. This difference was highly statistically significant, meaning it’s very unlikely to have occurred by chance. Vitamin D levels independently predicted excellent treatment response, meaning that even after accounting for other factors, higher vitamin D remained a strong predictor. The relationship held true even at lower improvement thresholds: vitamin D predicted at least 75% improvement as well. Super-Responders, the group with the best outcomes, had lower body weight and lower inflammation markers compared to those who switched treatments frequently.
Body weight and inflammation markers also showed important patterns. Patients with higher body mass index were significantly less likely to be Super-Responders. Inflammation markers measured by C-reactive protein were higher in patients who frequently switched between different biologic medications, suggesting that inflammation may indicate treatment instability. Higher CRP levels reduced the odds of maintaining stable biologic therapy. These secondary findings suggest that multiple factors work together to predict treatment success, not just vitamin D alone.
Previous research has suggested links between vitamin D and psoriasis severity, but few studies have examined whether vitamin D predicts response to expensive biologic medications. This study adds to growing evidence that vitamin D plays a role in immune-mediated skin diseases. The findings align with research showing that inflammation markers like CRP are associated with treatment outcomes in various chronic diseases. However, this is one of the first studies to combine vitamin D, BMI, and CRP to predict biologic response specifically in psoriasis, making it a novel contribution to personalized medicine in dermatology.
This pilot study has several important limitations. First, it’s a cross-sectional study, meaning researchers measured everything at one time point and cannot prove that vitamin D causes better treatment response. Second, the sample size of 120 is relatively small for developing predictive algorithms. Third, the study was conducted at a single hospital in Northern Ireland, so findings may not apply to other populations or geographic regions with different sun exposure and dietary patterns. Fourth, the study did not measure other factors that might influence treatment response, such as genetics, specific biologic medication type, or duration of treatment. Finally, this is preliminary research, and the findings need validation in larger, prospective studies before clinical implementation.
The Bottom Line
Based on this pilot study, doctors might consider measuring vitamin D levels, body weight, and inflammation markers before starting biologic therapy for psoriasis. However, these findings are preliminary (confidence level: moderate). Patients should not make treatment decisions based solely on this single study. If you have psoriasis, discuss with your dermatologist whether vitamin D testing might be helpful for your situation. Maintaining adequate vitamin D levels through sun exposure, diet, or supplementation may be beneficial, though more research is needed to confirm this.
This research is most relevant to adults with moderate to severe psoriasis considering biologic therapy. Dermatologists and rheumatologists treating psoriasis should be aware of these findings as they develop personalized treatment plans. Patients who have not responded well to previous treatments might particularly benefit from vitamin D assessment. This research is less immediately relevant to people with mild psoriasis or those using other treatment types. People in regions with limited sun exposure may find this especially relevant.
If vitamin D is a factor in treatment response, improvements might be seen within weeks to months of starting biologic therapy, similar to typical treatment timelines. However, optimizing vitamin D levels before starting treatment might take several weeks. Realistic expectations are that biologic medications typically show measurable improvement within 4 to 12 weeks, and this timeline would not change based on vitamin D status.
Frequently Asked Questions
Can vitamin D levels predict if biologic psoriasis treatment will work for me?
A 2026 pilot study suggests vitamin D levels may help predict biologic treatment success. Patients with higher vitamin D had much better outcomes, but this is preliminary research. Ask your dermatologist whether vitamin D testing might be useful for your specific situation before starting treatment.
Should I take vitamin D supplements if I have psoriasis?
This study suggests adequate vitamin D may support better biologic treatment response, but it doesn’t prove supplementation will help. Discuss vitamin D levels with your doctor before starting supplements. Some people benefit from increased sun exposure or dietary sources instead of pills.
Does body weight affect how well psoriasis biologic medications work?
The 2026 study found that higher body weight was associated with worse biologic treatment response. Weight management may support better outcomes, but this is preliminary evidence. Work with your healthcare team on a personalized approach combining treatment and lifestyle factors.
What does C-reactive protein have to do with psoriasis treatment?
C-reactive protein measures inflammation in your blood. The study found that patients with higher inflammation markers were more likely to need to switch biologic medications, suggesting inflammation may indicate treatment instability. Your doctor can measure this with a simple blood test.
Is this study large enough to change how doctors treat psoriasis?
This is a pilot study with 120 patients, which is preliminary research. Larger studies are needed before doctors routinely use these measurements to predict treatment response. However, the findings are promising and suggest a direction for future personalized psoriasis care.
Want to Apply This Research?
- Track your vitamin D levels (measured in nmol/L or ng/mL), body weight, and any inflammation markers your doctor measures. Record these values monthly and note any changes in your psoriasis severity using a simple 1-10 scale. This creates a personal record to share with your dermatologist.
- If you have psoriasis and are starting biologic therapy, ask your doctor to check your vitamin D level before treatment begins. If levels are low, discuss vitamin D supplementation or increased sun exposure. Monitor your weight and discuss any changes with your healthcare provider, as the study suggests weight management may support better treatment outcomes.
- Create a quarterly check-in routine where you record your vitamin D levels, current weight, and psoriasis improvement percentage. Share this data with your dermatologist at each visit to help refine your personalized treatment plan. If you’re on biologic therapy, track how stable your treatment remains and whether you need to switch medications.
This article summarizes preliminary research from a pilot study and should not replace professional medical advice. Vitamin D levels, body weight, and inflammation markers may be associated with biologic treatment response, but this does not prove causation. Do not start, stop, or change psoriasis medications based on this information. Always consult with your dermatologist or rheumatologist before making treatment decisions. Individual responses to biologic therapy vary, and multiple factors influence treatment success. This research is not yet standard clinical practice and requires validation in larger studies.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.